& stable medical Cannabis products
Dr. Arnon Heyman is the CEO of Canonic Ltd. Dr. Heyman has previously served as VP and GM of Evogene’s Ag-Seeds division managing all plant genetics activities and related collaborations. Prior to Evogene, Dr. Heyman served as CTO of BondX Technologies Ltd. from 2009-2014.
Dr. Heyman holds a PhD. In Biotechnology from the Hebrew University in Jerusalem (2008) and a MBA from the College of Management (2015).
Dr. Inbal Dangoor is an experienced plant scientist with expertise in genetics, biotechnology and computational biology. Prior to joining Canonic, Dr. Dangoor managed the New Breeding Technologies activities of Evogene and was the Corn research team leader in the Yield and Abiotic Stress division.
Dr. Dangoor holds a Ph.D. from the Weizmann Institute of Science in Rehovot (2010).
Ofer Haviv holds the position of Evogene’s President and CEO as of late 2004. During his time at Evogene, he led two IPOs, in the Tel Aviv stock exchange (2008) and NYSE (2013). Additionally, during these years, Evogene had initiated several multi-year collaborations with world leading companies such as: Monsanto, BASF, Bayer, Corteva, Syngenta and ICL, to name a few.
Ms. Dorit Kreiner was appointed as CFO in February 2019, bringing over 20 years of senior financial management experience. She previously served as Chief Financial Officer in Therapix (TASE: THXBY) and NRGene. In addition, Ms. Kreiner served as Director of Finance of Evogene from June 2004 through August 2011.
Ms. Kreiner holds a BA in accounting and economics and an MBA in Finance and Marketing, both from Tel Aviv University, and a Bachelor of Law from the College of Management.